Mumbai (Maharashtra) [India], May 3: To commemorate the 25th year of the listing of Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) on the National Stock Exchange of India (NSE), a bell ringing ceremony was organized at BKC, Mumbai on 2nd May 2025. On this occasion, senior
Ahmedabad (Gujarat) [India], March 14: In a significant stride towards making advanced cancer treatment accessible to all, Zydus has launched Olaparib, a PARP inhibitor, under the brand name IBYRA in India. The drug will target specific genetic mutations prevalent in certain types of cancers
Ahmedabad (Gujarat) [India], November 7: Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and half year ended September 30th, 2023.
New Delhi [India], August 21 (ANI): Managing Director of Zydus Group Dr Sharvil Patel on Saturday said that his firm will soon apply for the Indian drug regulator's approval to conduct trials of ZyCoV-D on children above 2 years and added that it will take another 4-5 months to publish the p
New Delhi [India], August 21 (ANI): There will be more clarity on the price of its COVID-19 vaccine ZyCOV-D by next week, said Managing Director of Zydus Group Dr Sharvil Patel on Saturday.
New Delhi [India], July 1 (ANI): The pharmaceutical firm Zydus Cadila on Thursday informed that it has applied for emergency use authorisation (EUA) from the Drug Controller General of India (DCGI) for its DNA vaccine ZyCoV-D against coronavirus disease and stated that they expect to produce